|Bid||63.47 x 100|
|Ask||64.39 x 100|
|Day's Range||63.41 - 64.37|
|52 Week Range||46.01 - 66.10|
|PE Ratio (TTM)||23.44|
|Dividend & Yield||1.56 (2.39%)|
|1y Target Est||N/A|
Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.
Is it time to get cautious on Bristol-Myers Squibb (BMY). The drug maker’s share price is falling today after Jefferies analyst Jeffrey Holford downgraded the stock from a Buy to a Hold, and shaved his 12-month price target by a dollar to $71 a share. Sure, Holford sees Bristol-Myers as a leading player in the immuno-oncology market and believes that the Street may be underestimating the potential for some of its drugs, namely the diverse set of indications it is pursuing for the cancer drug cocktail composed of Opdivo and Yervoy.
Stocks look set for a higher open this morning after the Dow and S&P closed just below new highs last week. S&P 500 futures have ticked up 0.1%, while Dow Jones Industrial Average futures have advanced ...
Bristol-Myers Squibb (BMY: NYSE) Guggenheim Securities ($65.11, Oct. 12, 2017) We are raising our price target for Bristol-Myers Squibb to $75 from $68. Our ...
Investors rolled into shares of Apple in September, according to TD Ameritrade, but took profits on shares of Bristol-Myers and Pfizer shares.
Bristol-Myers Squibb Company (NYSE:BMY) delivered an ROE of 30.51% over the past 12 months, which is an impressive feat relative to its industry average of 18.27% during the same period.Read More...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $5.51 billion.
Two of the biggest pharma stocks with two of the most successful cancer drugs. But which is the better pick for investors?
Bristol-Myers Squibb continues to trade higher and no one's going to leave the stock behind in this kind of market, Jim Cramer says.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $1.93 billion.
Stillwater, MN, based Investment company Stillwater Investment Management, LLC buys DowDuPont Inc, Bristol-Myers Squibb Company during the 3-months ended 2017-09-30, according to the most recent filings ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $1.07 billion.
Bristol-Myers Squibb (BMY), a US pharmaceutical company, includes innovative products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises.
Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.
Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis, developed in alliance with Pfizer (PFE).